临床实践推荐，尼斯/圣保罗-德-旺斯 2022-2023年：局限性子宫内膜癌的管理 子宫内膜癌是工业化国家最常见的妇科癌症，其发病率不断增加。新的分子分类法使得能够确定复发风险，并帮助指导治疗管理。手术仍然是治疗的基石。对于I期和II期，应优先选择微创手术方式。手术包括子宫切除术与双侧附件切除术，即使在高风险疾病中也要进行前哨淋巴结活检和除去网膜腹腔镜检查非子宫内膜状肿瘤（除非为明胞状肿瘤）时。对于低级别、I期肿瘤且没有子宫肌层侵犯的患者，可以提供保存生育能力的治疗。在III期/IV期疾病中，适用于进行淋巴结灶块清除但不进行全淋巴结清除术。在腹膜转移癌的情况下，如果可以实现完全切除，则推荐进行一线细胞减量手术。对于低风险肿瘤不推荐辅助治疗。在中等风险肿瘤中，应使用放射性治疗。对于高中等风险肿瘤，应根据预后因素（II期、淋巴管膜侵犯）选择放射性治疗和外部放疗；可以根据个案考虑进行辅助化疗。对于高风险肿瘤，推荐使用同时或顺序化接受化疗和外部放疗的方法。 版权所有 © 2023 Elsevier Masson SAS. 保留所有权利。

Recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of localized endometrial cancer Endometrial cancer is the most frequent gynecological cancers in industrialized countries and its incidence increases. The newmolecularclassification allows determination of the risk of recurrence and helps orienting therapeutic management. Surgery remains the cornerstone of treatment. Minimally invasive approach must be preferred for stages I and II. Surgery includes hysterectomy with bilateral adnexectomy, sentinel lymph node biopsy even in high risk diseases and omentectomy for non-endometrioid tumors (except in case of clear cells tumors). Fertility preservation can be proposed in low grade, stage I tumors without myometrial involvement. In stage III/IV disease, lymph node debulking without totallymphadenectomy is indicated. In case of peritoneal carcinomatosis, first-line cytoreductive surgery is recommended if complete resection can be achieved. Adjuvant therapy is not recommended in low risk tumors. In intermediate risk tumors, curietherapy is indicated. In tumors with high-intermediate risk, curietherapy and external radiotherapy are indicated according to prognostic factors (stage II, lymphovascular invasion); adjuvant chemotherapy can be considered on a case-by-case basis. In high risk tumors, chemotherapy and external radiotherapy are recommended using a concomitant or sequential approach.Copyright © 2023 Elsevier Masson SAS. Tous droits réservés. All rights reserved.